In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.